Blood Donors on Teratogenic Drugs and Donor Deferral Periods in a Clinical Situation

    December 2011 in “ Vox Sanguinis ”
    Soo Youn Shin, Young Hack Shin, S. W. Lee, Jong-Il Shin, C. H. Kim
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Studysummary This study found that blood samples from donors on teratogenic drugs sometimes exceeded recommended concentration limits, suggesting a need for improved deferral policies. Our plain-language summary of this paper — not a Tressless recommendation.
    The study analyzed 167 stored blood specimens from donors who had taken teratogenic drugs and whose blood was transfused to women of childbearing age. The aim was to determine the plasma concentration of these drugs at the time of donation using high-performance liquid chromatography. The results showed that the numbers of specimens exceeding the quantification limit were 7 for finasteride, 39 for isotretinoin, 4 for acitretin, 2 for etretinate, and 1 for dutasteride. Notably, one specimen of finasteride was beyond the recommended drug deferral period. These findings were intended to aid in the development of practical deferral policies for blood donors on teratogenic medications.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results